We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

97 hedge funds and large institutions have $52.9M invested in Lineage Cell Therapeutics in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.34% more ownership

Funds ownership: 42.29% → 42.63% (+0.34%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less capital invested

Capital invested by funds: $56.4M → $52.9M (-$3.5M)

10% less funds holding

Funds holding: 108 → 97 (-11)

33% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 27

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

Holders
97
Holders Change
-11
Holders Change %
-10.19%
% of All Funds
2.14%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
7
Increased
18
Reduced
27
Closed
16
Calls
$138K
Puts
–
Net Calls
+$138K
Net Calls Change
+$140K

Top Buyers

Rank Fund Capital Flow
1
DC
Defender Capital
North Carolina
+$438K
2
Renaissance Technologies
Renaissance Technologies
New York
+$267K
3
Jane Street
Jane Street
New York
+$141K
4
Northern Trust
Northern Trust
Illinois
+$124K
5
Wells Fargo
Wells Fargo
California
+$118K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$190K
2
Morgan Stanley
Morgan Stanley
New York
-$138K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$84.9K
4
UBS Group
UBS Group
Switzerland
-$84.6K
5
Creative Planning
Creative Planning
Kansas
-$83.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
RFA
76
Reilly Financial Advisors
California
$2K – – –
Osaic Holdings
77
Osaic Holdings
Arizona
$2K +$2.85K +2,861 New
AIC
78
Ameritas Investment Company
Nebraska
$2K +$2.99K +3,000 New
AIC
79
Archer Investment Corporation
Indiana
$1K – – –
Fifth Third Bancorp
80
Fifth Third Bancorp
Ohio
$1K – – –
IA
81
IFP Advisors
Florida
$1K – – –
GEA
82
Glen Eagle Advisors
New Jersey
$922 -$747 -750 -40%
APA
83
American Portfolios Advisors
New York
$12 – – –
OAM
84
Oxford Asset Management
United Kingdom
– -$35K -39,842 Closed
ARTA
85
A.R.T. Advisors
New York
– -$29K -32,225 Closed
RJFSA
86
Raymond James Financial Services Advisors
Florida
– -$18K -19,860 Closed
Prudential Financial
87
Prudential Financial
New Jersey
– -$18K -19,698 Closed
ProShare Advisors
88
ProShare Advisors
Maryland
– -$13K -14,661 Closed
NA
89
NewEdge Advisors
Louisiana
– -$8K -10,000 Closed
HPC
90
HM Payson & Co
Maine
– -$2K -2,650 Closed
Rockefeller Capital Management
91
Rockefeller Capital Management
New York
– -$1K -1,100 Closed
FCA
92
FinTrust Capital Advisors
South Carolina
– -$1K -631 Closed
Simplex Trading
93
Simplex Trading
Illinois
– -$85 -85 Closed
Federated Hermes
94
Federated Hermes
Pennsylvania
– -$1K -20 Closed
SHWM
95
Silicon Hills Wealth Management
Texas
– -$3 -1 Closed
EWM
96
EPG Wealth Management
Georgia
– +$14 +14 New
1 2 3
4

LCTX Hedge Fund Activity: Q1 2020 in Review

97 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2020, worth a combined $52.9M — down 6.2% from $56.4M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of LCTX and 7 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 18 added.

The largest buyer was Defender Capital, adding an estimated $438K. The largest seller was Two Sigma Investments, cutting an estimated $190K.

  • 97 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2020, down from 108 in Q4 2019.
  • Funds reported $52.9M of Lineage Cell Therapeutics stock for Q1 2020, down 6.2% quarter-over-quarter.
  • 7 funds opened new Lineage Cell Therapeutics positions in Q1 2020 and 16 closed out, a net change of -9 holders.
  • The largest Lineage Cell Therapeutics buyer in Q1 2020 was Defender Capital, an estimated $438K added.
  • The largest Lineage Cell Therapeutics seller in Q1 2020 was Two Sigma Investments, an estimated $190K sold.

Based on aggregated 13F filings for Q1 2020.